Since NFκB is considered an excellent target for anticancer therapy and its inhibition by Rottlerin has been also documented in human colon adenocarcinoma HT29 cells [4], Rottlerin was expected to interrupt the process of cancer progression at multiple levels and in different cells. The gene discussed is NFKB1; the disease is cancer.